Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gun Park

Showing results (241-250 of 318) with videos related to

Pageof 32
Sort By:
Nanomaterials (Basel, Switzerland)|August 27, 2025
Effects of Hydrolysis Reaction and Abrasive Drag Force Accelerator on Enhancing Si-Wafer Polishing Rate and Improving Si-Wafer Surface RoughnessMin-Uk Jeon, Pil-Su Kim, Man-Hyup Han, et al.
European Journal of Heart Failure|March 29, 2023
Serial assessment of biomarkers and heart failure outcomes in patients with atrial fibrillationKazuma Oyama, Robert P Giugliano, Christian T Ruff, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 1, 2011
Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267Kelly E Dooley, Jeong-Gun Park, Susan Swindells, et al.
Journal of the American College of Cardiology|August 24, 2019
Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT TrialArman Qamar, Robert P Giugliano, Erin A Bohula, et al.
Antimicrobial Agents and Chemotherapy|July 29, 2005
Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitorsPatrick F Smith, Gregory K Robbins, Robert W Shafer, et al.
JAMA Cardiology|March 15, 2017
Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT TrialRobert P Giugliano, Stephen D Wiviott, Michael A Blazing, et al.
ACS Applied Materials & Interfaces|June 28, 2023
Scalable Solution Phase Synthesis of 2D Siloxene <i>via</i> a Two-Step Interlayer Expansion ProcessSeung-Bo Ko, Yan Sun, Gun Park, et al.
American Heart Journal|September 11, 2021
Inhibition of p38 MAP kinase in patients with ST-elevation myocardial infarction - findings from the LATITUDE-TIMI 60 trialMatthew A Cavender, Michelle L O'Donoghue, Antonio Abbate, et al.
Antimicrobial Agents and Chemotherapy|June 25, 2014
Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampinKelly E Dooley, Anne F Luetkemeyer, Jeong-Gun Park, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|January 15, 2021
Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trialSarah E Nelson, Robert P Giugliano, Elliott M Antman, et al.
Pageof 32

Showing results (241-250 of 318) with videos related to

Sort By:
Pageof 32
Nanomaterials (Basel, Switzerland)|August 27, 2025
Effects of Hydrolysis Reaction and Abrasive Drag Force Accelerator on Enhancing Si-Wafer Polishing Rate and Improving Si-Wafer Surface RoughnessMin-Uk Jeon, Pil-Su Kim, Man-Hyup Han, et al.
European Journal of Heart Failure|March 29, 2023
Serial assessment of biomarkers and heart failure outcomes in patients with atrial fibrillationKazuma Oyama, Robert P Giugliano, Christian T Ruff, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 1, 2011
Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267Kelly E Dooley, Jeong-Gun Park, Susan Swindells, et al.
Journal of the American College of Cardiology|August 24, 2019
Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT TrialArman Qamar, Robert P Giugliano, Erin A Bohula, et al.
Antimicrobial Agents and Chemotherapy|July 29, 2005
Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitorsPatrick F Smith, Gregory K Robbins, Robert W Shafer, et al.
JAMA Cardiology|March 15, 2017
Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT TrialRobert P Giugliano, Stephen D Wiviott, Michael A Blazing, et al.
ACS Applied Materials & Interfaces|June 28, 2023
Scalable Solution Phase Synthesis of 2D Siloxene <i>via</i> a Two-Step Interlayer Expansion ProcessSeung-Bo Ko, Yan Sun, Gun Park, et al.
American Heart Journal|September 11, 2021
Inhibition of p38 MAP kinase in patients with ST-elevation myocardial infarction - findings from the LATITUDE-TIMI 60 trialMatthew A Cavender, Michelle L O'Donoghue, Antonio Abbate, et al.
Antimicrobial Agents and Chemotherapy|June 25, 2014
Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampinKelly E Dooley, Anne F Luetkemeyer, Jeong-Gun Park, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|January 15, 2021
Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trialSarah E Nelson, Robert P Giugliano, Elliott M Antman, et al.
Pageof 32